EUVIMEDEUVIMED entdecken
Multizentrische StudieKohortenstudie

Effectiveness and Safety of Qishen Yiqi Dripping Pill in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: 3-Year Results from a Multicentre Cohort Study

Rui-Na Bai, Feng Gu, Qian-Zi Che, Xuan Zhang, Ya-Jie Cai, Rui-Xi Xi, Yang Zhao, Ming Guo, Guo-Ju Dong, Zhu-Ye Gao, Chang-Geng Fu, Pei-Li Wang und 6 weitere

Chinese Journal of Integrative Medicine · 2024

DOI: 10.1007/s11655-024-3664-1 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Chinese Journal of Integrative Medicine, 2024. Verfasst von Rui-Na Bai und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Drugs, Chinese Herbal, Percutaneous Coronary Intervention. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 29 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVES: To evaluate the effectiveness and safety of Qishen Yiqi Dripping Pill (QSYQ) in patients with acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI). METHODS: This multicentre prospective cohort study was conducted at 40 centers in China. Patients with ACS after PCI entered either the QSYQ or Western medicine (WM) groups naturally based on whether they had received QSYQ before enrollment. QSYQ group received QSYQ (0.52 g, 3 times a day for 12 months) in addition to WM. The primary endpoint included cardiac death, non-fatal myocardial infarction, and urgent revascularization. The secondary endpoint included rehospitalization due to ACS, heart failure, stroke, and other thrombotic events. Quality of life was assessed by the Seattle Angina Questionnaire (SAQ). RESULTS: A total of 936 patients completed follow-up of the primary endpoint from February 2012 to December 2018. Overall, 487 patients received QSYQ and WM. During a median follow-up of 566 days (inter quartile range, IQR, 517-602), the primary endpoint occurred in 46 (9.45%) and 65 (14.48%) patients in QSYQ and WM groups respectively [adjusted hazard ratio (HR) 0.60, 95% confidence interval (CI) 0.41-0.90; P=0.013]. The secondary endpoint occurred in 61 (12.53%) and 74 (16.48%) patients in QSYQ and WM groups, respectively (adjusted HR 0.76, 95% CI 0.53-1.09; P=0.136). In sensitivity analysis, the results still demonstrated that WM combined with QSYQ reduced the risk of the primary endpoint (HR 0.67, 95% CI 0.46-0.98; P=0.039). Moreover, QSYQ improved the disease perception domain of the SAQ (P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromeDrugs, Chinese HerbalPercutaneous Coronary InterventionHumansMaleFemaleMiddle AgedAgedTreatment OutcomeProspective StudiesCohort StudiesQuality of Life

Stichwörter der Autor:innen

Qishen Yiqi Dripping Pillacute coronary syndromepercutaneous coronary interventionprimary and secondary endpoint

Substanzen

Drugs, Chinese Herbalqishen yiqi

Autor:innen und Institutionen

  • Department of Cardiovascular, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China.
  • National Clinical Research Center for Chinese Medicine Cardiology, Beijing, 100091, China.
  • Department of Evidence-Based Medicine Basic Research Laboratory, Institute of Basic Research in Clinical Medicine, China Academy of Chinese Medical Sciences, Beijing, 100700, China.
  • Department of Traditional Chinese Medicine, Beijing Shangdi Hospital, Beijing, 100193, China.
  • National Medical Products Administration, Key Laboratory for Clinical Research and Evaluation of Traditional Chinese Medicine, Beijing, 100091, China.
  • Department of Cardiovascular, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, 100091, China. shidztcm@163.com.

Zitieren

APA

Bai, R. N., Gu, F., Che, Q. Z., Zhang, X., Cai, Y. J., Xi, R. X., Zhao, Y., Guo, M., Dong, G. J., Gao, Z. Y., Fu, C. G., Wang, P. L., Du, J. P., Zhang, D. W., Duan, W. H., Li, L. Z., Yang, Q. N., & Shi, D. Z. (2024). Effectiveness and Safety of Qishen Yiqi Dripping Pill in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: 3-Year Results from a Multicentre Cohort Study. Chinese Journal of Integrative Medicine. https://doi.org/10.1007/s11655-024-3664-1

Vancouver

Bai RN, Gu F, Che QZ, Zhang X, Cai YJ, Xi RX, et al. Effectiveness and Safety of Qishen Yiqi Dripping Pill in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: 3-Year Results from a Multicentre Cohort Study. Chinese Journal of Integrative Medicine. 2024. doi:10.1007/s11655-024-3664-1

BibTeX
@article{Bai2024,
  author = {Bai, Rui-Na and Gu, Feng and Che, Qian-Zi and Zhang, Xuan and Cai, Ya-Jie and Xi, Rui-Xi and Zhao, Yang and Guo, Ming and Dong, Guo-Ju and Gao, Zhu-Ye and Fu, Chang-Geng and Wang, Pei-Li and Du, Jian-Peng and Zhang, Da-Wu and Duan, Wen-Hui and Li, Li-Zhi and Yang, Qiao-Ning and Shi, Da-Zhuo},
  title = {Effectiveness and Safety of Qishen Yiqi Dripping Pill in Patients with Acute Coronary Syndrome after Percutaneous Coronary Intervention: 3-Year Results from a Multicentre Cohort Study},
  journal = {Chinese Journal of Integrative Medicine},
  year = {2024},
  doi = {10.1007/s11655-024-3664-1}
}
Kostenlos starten →